EU approves Celgene's pomalidomide for multiple myeloma

08/12/2013 | PharmaTimes (U.K.)

Celgene obtained approval from the European Commission to market pomalidomide in combination with dexamethasone for adults with relapsed and refractory multiple myeloma. The drug is specifically indicated for patients who have received at least two therapies and whose disease have worsened with the most recent treatment. The drug will be sold as Imnovid in Europe.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC